目的 探討康婦炎膠囊聯(lián)合頭孢噻肟鈉治療子宮內(nèi)膜炎的臨床療效。方法 選取2018年5月-2019年5月在眉山市人民醫(yī)院治療的子宮內(nèi)膜炎患者84例，根據(jù)用藥的差別分為對(duì)照組（42例）和治療組（42例）。對(duì)照組靜脈滴注注射用頭孢噻肟鈉，2.0 g/次加入生理鹽水100 mL，2次/d；治療組在對(duì)照組基礎(chǔ)上口服康婦炎膠囊，1.2 g/次，3次/d。兩組均治療2周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者臨床癥狀積分，GQOLI-74、FSFI和VAS評(píng)分，及血清C反應(yīng)蛋白（CRP）、白細(xì)胞介素-4（IL-4）、白細(xì)胞介素-8（IL-8）、腫瘤壞死因子-α（TNF-α）和基質(zhì)金屬蛋白酶-2（MMP-2）水平。結(jié)果 治療后，對(duì)照組臨床有效率為80.95%，顯著低于治療組的97.62%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，兩組患者癥狀評(píng)分均顯著下降（P<0.05），且治療組比對(duì)照組下降更明顯（P<0.05）。經(jīng)治療，兩組患者GQOLI-74評(píng)分明顯升高（P<0.05），而FSFI和VAS評(píng)分均明顯降低（P<0.05），且治療組GQOLI-74、FSFI和VAS評(píng)分明顯好于對(duì)照組（P<0.05）。經(jīng)治療，兩組患者血清CRP、IL-4、IL-8、TNF-α、MMP-9水平均顯著降低（P<0.05），且治療組患者明顯低于對(duì)照組（P<0.05）。結(jié)論 康婦炎膠囊聯(lián)合注射用頭孢噻肟鈉治療子宮內(nèi)膜炎患者可有效改善患者臨床癥狀，降低機(jī)體炎癥反應(yīng)，提高患者性生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Kangfuyan Capsules combined with cefotaxime sodium in treatment of endometritis. Methods Patients (84 cases) with endometritis in Meishan People's Hospital from May 2018 to May 2019 were divided into control (42 cases) and treatment (42 cases) groups based on different treatments. Patients in the control group were iv administered with Cefotaxime Sodium for injection, 2 g added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Kangfuyan Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom score, the GQOLI-74, FSFI and VAS score, and the serum level of CRP, IL-4, IL-8, TNF-α, and MMP-2 in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 80.95%, which was significantly lower than 97.62% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the clinical symptom score in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the GQOLI-74 score in two groups was significantly increased (P<0.05), but the FSFI and VAS score was significantly decreased (P<0.05), and the GQOLI-74, FSFI and VAS score in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the serum level of CRP, IL-4, IL-8, TNF-α and MMP-2 in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Kangfuyan Capsules combined with cefotaxime sodium in treatment of endometritis can effectively improve the clinical symptoms, reduce inflammation and improve the quality of sexual life, which has a certain clinical application value.

R984

四川省衛(wèi)生和計(jì)劃生育委員會(huì)科研項(xiàng)目（18PJ068）